Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (258)

2024

  1. Approach to Mycosis Fungoides in children: Consensus-based recommendations

    Journal of the American Academy of Dermatology

  2. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.

    New England Journal of Medicine, Vol. 391, Núm. 11, pp. 1002-1014

  3. CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  4. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer

    Lung Cancer, Vol. 192

  5. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

    European Urology, Vol. 86, Núm. 1, pp. 4-9

  6. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma

    Leukemia and Lymphoma, Vol. 65, Núm. 3, pp. 323-332

  7. Comparison of Patient Health Questionnaire-9, Edinburgh Postnatal Depression Scale and Hospital Anxiety and Depression – Depression subscale scores by administration mode: An individual participant data differential item functioning meta-analysis

    Journal of Affective Disorders, Vol. 361, pp. 674-683

  8. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Blood, Vol. 143, Núm. 17, pp. 1713-1725

  9. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

    Lung Cancer, Vol. 188

  10. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

    European Urology

  11. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

    Molecular Cancer, Vol. 23, Núm. 1

  12. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 1026-1038

  13. Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists

    Histopathology, Vol. 84, Núm. 3, pp. 429-439

  14. Skull base surgery for malignant tumors: The 2nd international collaborative study (1995–2015)

    Head and Neck

  15. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023

    Transplant Infectious Disease, Vol. 26, Núm. 1

2023

  1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248

  2. Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer

    Cancers, Vol. 15, Núm. 5

  3. Association between use of enhanced recovery after surgery protocols and postoperative complications after gastric surgery for cancer (POWER 4): a nationwide, prospective multicentre study

    Cirugia Espanola, Vol. 101, Núm. 10, pp. 665-677

  4. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10415, pp. 1835-1847

  5. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia